510 related articles for article (PubMed ID: 33424844)
1. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
Front Immunol; 2020; 11():596825. PubMed ID: 33424844
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
7. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
8. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
[TBL] [Abstract][Full Text] [Related]
10. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
11. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
13. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
[TBL] [Abstract][Full Text] [Related]
14. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract][Full Text] [Related]
16. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease.
Kawaguchi A; Akiba J; Kondo R; Sadashima E; Ogasawara S; Naito Y; Kusano H; Sanada S; Muto I; Nakama T; Yano H
Anticancer Res; 2021 Jan; 41(1):219-226. PubMed ID: 33419816
[TBL] [Abstract][Full Text] [Related]
19. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
Gupta S; Vanderbilt CM; Cotzia P; Arias-Stella JA; Chang JC; Zehir A; Benayed R; Nafa K; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME; Ross DS
J Mol Diagn; 2019 Mar; 21(2):307-317. PubMed ID: 30576871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]